Autolus Therapeutics (AUTL) announces pivotal Phase 2 FELIX clinical trial has met primary endpoint at interim analysis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/16/2026

1. VRNS
2. CRWV
3. JBHT
4. TSLA
5. SCHW
6. GPRK
7. TRV
8. TFC
9. NEST:IN
10. AA

Go back to Autolus Therapeutics (AUTL) announces pivotal Phase 2 FELIX clinical trial has met primary endpoint at interim analysis

Autolus Therapeutics (AUTL) Announces Proposed Public Offering in the United States

December 8, 2022 4:04 PM EST

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it has commenced an underwritten public offering of American Depositary Shares (ADSs), each ADS representing one ordinary share. All ADSs to be sold in the proposed... More

Autolus Therapeutics (AUTL) to Receive $70 Million in Milestone Payments from Blackstone Life Sciences

December 8, 2022 4:03 PM EST

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that Blackstone Life Sciences (Blackstone) has committed to make two pre-agreed milestone payments of $35m each to Autolus, totaling $70m. The milestones are expected to be recognized in Autolus Q4 2022 cash balance.

The first Blackstone milestone of $35m is being paid earlier than anticipated as a result of the joint steering committees review of Autolus interim analysis of pivotal FELIX Phase 2... More